<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>TATVA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">TATVA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="tatva-chintan-pharma-chem-limited" class="section level1">
<h1>Tatva Chintan Pharma Chem Limited</h1>
<p><a href="/reports01/index/industry/rp-SpecialtyChemicals.html">Specialty Chemicals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.TATVA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="comprehensive-analysis-of-tatva-chintan-pharma-chem-limited-tatva-nse-scrip-code-543321-isin-ine0gk401011" class="section level9">
<p class="heading"><strong>Comprehensive Analysis of Tatva Chintan Pharma Chem Limited (TATVA: NSE, Scrip Code: 543321, ISIN: INE0GK401011)</strong></p>
<p>Based on the provided Annual General Meeting (AGM) e-voting results, Scrutinizer’s Report, and related corporate disclosures, here is a detailed <strong>analysis of headwinds, tailwinds, growth prospects, and key risks</strong> for <strong>Tatva Chintan Pharma Chem Limited (TATVA)</strong>.</p>
<hr />
</div>
<div id="i.-executive-summary-key-highlights" class="section level6">
<h6><strong>I. Executive Summary: Key Highlights</strong></h6>
<ul>
<li><strong>Meeting Date</strong>: 26 September 2025<br />
</li>
<li><strong>All 12 Resolutions Passed</strong>, including approval of financials, dividends, re-appointments of key executives, and auditors.</li>
<li><strong>High Shareholder Support</strong>: Promoters hold 72% of shares; resolutions passed with &gt;99.9% in favor, except for key management reappointments.</li>
<li><strong>Low Shareholder Participation</strong>: Only <strong>50 shareholders</strong> participated via VC/OAVM (11 Promoters + 39 Public), despite 74,978 on record date.</li>
<li><strong>Voting Almost Entirely Remote</strong>: All votes cast via remote e-voting; zero votes during live AGM.<br />
</li>
<li><strong>Director Reappointment with Minor Opposition</strong>:
<ul>
<li><strong>Chintan Shah (MD)</strong>: Received only <strong>96.91%</strong> in favor — lowest among key resolutions.</li>
<li>Others received &gt;99.9%, indicating strong confidence from investor base except slight dissent on MD’s remuneration.</li>
</ul></li>
<li><strong>Investor Engagement</strong>: Scheduled meeting with <strong>Sequent Investments</strong> (a known institutional investor) confirms active investor relations.</li>
</ul>
<hr />
</div>
<div id="ii.-tailwinds-positive-catalysts" class="section level6">
<h6><strong>II. Tailwinds (Positive Catalysts)</strong></h6>
<div id="strong-promoter-confidence-control" class="section level9">
<p class="heading"><strong>1. Strong Promoter Confidence &amp; Control</strong></p>
<ul>
<li>Promoter and Promoter Group hold <strong>16.85 million shares (~72%)</strong>, almost entirely voting unanimously (100%) in favor of all resolutions.</li>
<li>High promoter shareholding <strong>ensures alignment of interests</strong> and strategic continuity.</li>
<li>Promoter participation via VC indicates <strong>active oversight</strong> of governance.</li>
</ul>
</div>
<div id="high-shareholder-approval-across-governance-measures" class="section level9">
<p class="heading"><strong>2. High Shareholder Approval Across Governance Measures</strong></p>
<ul>
<li><strong>All resolutions passed easily</strong>, including financial statements adoption and dividend declaration, reflecting <strong>broad investor approval of performance</strong>.</li>
<li>Appointment of auditors and secretarial auditors passed with &gt;99.9% support — reflects <strong>trust in financial and compliance hygiene</strong>.</li>
</ul>
</div>
<div id="transparent-compliant-e-voting-process" class="section level9">
<p class="heading"><strong>3. Transparent &amp; Compliant E-Voting Process</strong></p>
<ul>
<li>Full compliance with <strong>SEBI LODR, Companies Act 2013, and MCA/SEBI circulars</strong> for remote e-voting.</li>
<li>Appointment of independent scrutineer (TNT &amp; Associates), data unblocked in presence of witnesses.</li>
<li>E-voting facilitated via <strong>MUFG Intime</strong>, a professional agency — reduces risk of disputes.</li>
</ul>
</div>
<div id="dividend-declaration-indicates-profitability" class="section level9">
<p class="heading"><strong>4. Dividend Declaration Indicates Profitability</strong></p>
<ul>
<li>Resolution to declare dividend passed with overwhelming support (<strong>&gt;99.9%</strong>), confirming <strong>profit generation and willingness to return capital</strong> to shareholders.</li>
</ul>
</div>
<div id="scheduled-investor-meetings-signal-investor-relations-maturity" class="section level9">
<p class="heading"><strong>5. Scheduled Investor Meetings Signal Investor Relations Maturity</strong></p>
<ul>
<li>Engagement with <strong>Sequent Investments</strong> (a reputed fund) reflects proactive outreach to long-term institutional investors.</li>
<li>Company confirms <strong>no dissemination of UPSI</strong>, reinforcing adherence to SEBI’s insider trading norms.</li>
</ul>
<hr />
</div>
</div>
<div id="iii.-headwinds-concerns" class="section level6">
<h6><strong>III. Headwinds &amp; Concerns</strong></h6>
<div id="extremely-low-retail-shareholder-participation" class="section level9">
<p class="heading"><strong>1. Extremely Low Retail Shareholder Participation</strong></p>
<ul>
<li>Despite 74,978 registered shareholders, <strong>only 39 public shareholders (non-promoter) participated</strong> in voting — less than <strong>0.05%</strong>.</li>
<li><strong>Risk of disconnect</strong>: High resolution approval rates may reflect promoter dominance rather than broad-based sentiment.</li>
</ul>
</div>
<div id="dissent-on-managing-directors-re-appointment" class="section level9">
<p class="heading"><strong>2. Dissent on Managing Director’s Re-Appointment</strong></p>
<ul>
<li>MD <strong>Chintan Nitinkumar Shah</strong>’s re-appointment received <strong>3.0858% votes against (570,109 shares)</strong>, a significant number in relative terms.</li>
<li>This is the <strong>highest opposition</strong> recorded among all resolutions.</li>
<li>Public institutions (mutual funds, FIIs) accounted for majority of “against” votes (569,987 votes from Institutions vs. 122 from Non-Institutions).</li>
<li>May indicate <strong>concerns about high remuneration, performance, or governance style</strong> among institutional investors.</li>
</ul>
</div>
<div id="limited-transparency-on-proxyphysical-attendance" class="section level9">
<p class="heading"><strong>3. Limited Transparency on Proxy/Physical Attendance</strong></p>
<ul>
<li>The report shows <strong>0 attendees in person or through proxy</strong> — all votes via remote e-voting.</li>
<li>While permitted under virtual AGM norms, lack of live participation may raise <strong>questions on stakeholder engagement</strong>.</li>
</ul>
</div>
<div id="weak-branding-in-public-markets" class="section level9">
<p class="heading"><strong>4. Weak Branding in Public Markets</strong></p>
<ul>
<li>Despite being listed, the company’s <strong>digital presence and investor communication appear limited</strong> to mandated disclosures.</li>
<li>Investor meeting is scheduled nearly <strong>two months after AGM</strong> — slight lag in proactive engagement.</li>
</ul>
<hr />
</div>
</div>
<div id="iv.-growth-prospects" class="section level6">
<h6><strong>IV. Growth Prospects</strong></h6>
<div id="stable-leadership-governance-team" class="section level9">
<p class="heading"><strong>1. Stable Leadership &amp; Governance Team</strong></p>
<ul>
<li>Re-appointment of MD, Whole-time Directors, and Independent Directors ensures <strong>continuity of management strategy</strong>.</li>
<li>Independent Directors retained in full — supports <strong>board independence</strong> required by SEBI LODR.</li>
</ul>
</div>
<div id="rd-and-regulatory-strength" class="section level9">
<p class="heading"><strong>2. R&amp;D and Regulatory Strength</strong></p>
<ul>
<li><strong>R&amp;D center approved by DSIR</strong> — enables tax benefits (Section 35(2AB)) and supports innovation in niche pharma/APIs.</li>
<li>Focus on <strong>custom synthesis, complex generics, and regulatory filings</strong> suggests capability in high-margin areas.</li>
</ul>
</div>
<div id="manufacturing-infrastructure" class="section level9">
<p class="heading"><strong>3. Manufacturing Infrastructure</strong></p>
<ul>
<li>Operating in <strong>Ankleshwar (GIDC)</strong> and <strong>Dahej SEZ (Gujarat)</strong> — strong chemical industrial base.</li>
<li><strong>SEZ unit offers export incentives</strong> — beneficial for overseas revenue.</li>
</ul>
</div>
<div id="potential-for-foreign-expansion" class="section level9">
<p class="heading"><strong>4. Potential for Foreign Expansion</strong></p>
<ul>
<li>Many Indian pharma companies with niche API/custom synthesis are expanding in:
<ul>
<li>North America (US ANDA)</li>
<li>Europe (CEP/COS)</li>
<li>Japan (J-Filing)</li>
</ul></li>
<li>TATVA likely leverages these opportunities — <strong>dividend payout supports confidence in free cash flow</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="v.-key-risks" class="section level6">
<h6><strong>V. Key Risks</strong></h6>
<table>
<colgroup>
<col width="51%" />
<col width="48%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Governance Risk</strong></td>
<td>High promoter control (72%) combined with low retail shareholder engagement may lead to <strong>entrenchment or insider-driven decisions</strong>. The dissent on MD’s remuneration is a red flag to monitor.</td>
</tr>
<tr class="even">
<td><strong>Reputational Risk</strong></td>
<td>If Institutional Investor concerns grow (e.g., around executive pay), it could affect stock valuation or ESG ratings.</td>
</tr>
<tr class="odd">
<td><strong>Operational Risk</strong></td>
<td>Chemical/pharma manufacturing involves <strong>regulatory scrutiny (FDA, EDQM, CDSCO)</strong>. Non-compliance could disrupt supply.</td>
</tr>
<tr class="even">
<td><strong>Market Risk</strong></td>
<td>Global pricing pressures on APIs and competitive landscape could affect margins.</td>
</tr>
<tr class="odd">
<td><strong>ESG &amp; Compliance</strong></td>
<td>Operating in chemical hubs like Ankleshwar and Dahej brings environmental compliance obligations. Any environmental incident could impact operations.</td>
</tr>
<tr class="even">
<td><strong>Succession Risk</strong></td>
<td>Heavy reliance on key individuals (Shah, Patel, Somani). Lack of visible succession plan.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="vi.-financial-health-indicators-inferred" class="section level6">
<h6><strong>VI. Financial Health Indicators (Inferred)</strong></h6>
<p>While audited statements are referenced, we can infer: - <strong>Profitability</strong>: Dividend declaration confirms net profits. - <strong>Stable Capital Structure</strong>: Promoter stability and retained earnings support reinvestment. - <strong>Low Leverage (likely)</strong>: No mention of debt/equity issues or capital raising — suggests organic growth. - <strong>Healthy Cash Flow</strong>: Ability to pay dividend, invest via Dahej SEZ, and offer executive remuneration.</p>
<hr />
</div>
<div id="vii.-conclusion-investment-outlook" class="section level6">
<h6><strong>VII. Conclusion: Investment Outlook</strong></h6>
<div id="rating-cautiously-positive" class="section level9">
<p class="heading"><strong>Rating: Cautiously Positive</strong></p>
</div>
<div id="strengths" class="section level9">
<p class="heading"><strong>Strengths</strong></p>
<ul>
<li>Strong promoter ownership and stable management.</li>
<li>Regulatory compliance and high governance standards (e.g., e-voting transparency).</li>
<li>Active investor engagement and DSIR-approved R&amp;D.</li>
<li>Dividend-paying track record indicates financial health.</li>
</ul>
</div>
<div id="concerns" class="section level9">
<p class="heading"><strong>Concerns</strong></p>
<ul>
<li>Low retail shareholder participation.</li>
<li>Institutional dissent on Managing Director’s remuneration.</li>
<li>Limited visibility into broader business strategy or segment performance.</li>
</ul>
</div>
<div id="recommendation-monitor-closely" class="section level9">
<p class="heading"><strong>Recommendation: Monitor Closely</strong></p>
<ul>
<li><strong>Short-term</strong>: Hold for dividend and stability.</li>
<li><strong>Long-term</strong>: Watch for:
<ul>
<li><strong>Institutional investor sentiment</strong> (esp. funds like Sequent Investments).</li>
<li><strong>Future AGM dissent levels</strong> — recurrence on MD/compensation items.</li>
<li>Expansion into regulated markets (FDA, EU).</li>
<li>ESG compliance, especially environmental standards.</li>
</ul></li>
</ul>
<blockquote>
<p>✅ <strong>Bottom Line</strong>: <em>Tatva Chintan is a well-managed, promoter-driven niche pharma player with stable governance and profit distribution. However, increased institutional scrutiny on executive compensation and low retail democracy suggest caution. Best suited for investors comfortable with controlled, non-consensus small-cap stocks with export pharma potential.</em></p>
</blockquote>
<hr />
</div>
</div>
<div id="appendix-key-data-snapshot" class="section level6">
<h6><strong>Appendix: Key Data Snapshot</strong></h6>
<table>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Promoter Holding</strong></td>
<td>~72% (16.85M out of 23.39M shares)</td>
</tr>
<tr class="even">
<td><strong>Total Outstanding Shares</strong></td>
<td>23,392,055</td>
</tr>
<tr class="odd">
<td><strong>Total Votes Polled</strong></td>
<td>18.48M (~79% of outstanding shares)</td>
</tr>
<tr class="even">
<td><strong>MD Reappointment “Against” Votes</strong></td>
<td>570,109 (3.09% of polled votes)</td>
</tr>
<tr class="odd">
<td><strong>Shareholder Count (Record Date)</strong></td>
<td>74,978</td>
</tr>
<tr class="even">
<td><strong>Live AGM Participants (Public)</strong></td>
<td>39 via VC, 0 in person/proxy</td>
</tr>
<tr class="odd">
<td><strong>Next Investor Meeting</strong></td>
<td>26 Nov 2025 (Virtual, Sequent Investments)</td>
</tr>
<tr class="even">
<td><strong>Compliance Officer</strong></td>
<td>Ishwar R. Nayi (CS, M. No: A37444)</td>
</tr>
<tr class="odd">
<td><strong>Scrutineer</strong></td>
<td>TNT &amp; Associates (CS: Niraj Trivedi)</td>
</tr>
</tbody>
</table>
<hr />
<p><em>Prepared as of 22 November 2025, based on public disclosures by Tatva Chintan Pharma Chem Limited.</em></p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
